Wuxi No.2 People's Hospital, 68 Zhongshan Road, Wuxi, 214000, Jiangsu, China.
Lipids Health Dis. 2018 Jun 23;17(1):146. doi: 10.1186/s12944-018-0797-2.
Patients with rheumatoid arthritis (RA) have an increased risk of coronary artery disease (CAD) above the baseline. Baicalin possesses beneficial effects against both RA and CAD, but little is know on its clincial efficacy among patients manifesting both CAD and RA.
Three hundred seventy four patients with CAD and RA were randomized to receive either 500 mg baicalin or placebo orally everyday for 12 weeks. Lipid profile, cardiotrophin-1 (CT-1), high sensitivity C-reactive protein (hs-CRP), European League Against Rheumatism (EULAR) response were analyzed at the end of study period.
After 12 week treatment, levels of triglycerides, total cholesterol, LDL-cholesterol and apolipoproteins, as well as CT-1 and hs-CRP, were all significantly improved in the baicalin group compared to the placebo group (1.12 ± 0.36 vs 1.87 ± 0.46 mmol/L, 2.87 ± 1.23 vs 3.22 ± 1.07 mmol/L, 1.38 ± 0.41 vs 1.16 ± 0.32 mmol/L, 1.31 ± 0.41 vs 1.23 ± 0.29 g/L, 42.9 ± 13.7 vs 128.4 ± 24.3 ng/mL, 1.64 ± 0.38 vs 3.9 ± 1.4 mg/dL, respectively). Significantly higher proportion of patients in the baicalin group (71%) reported good/moderate EULAR response than the placebo group (53%).
Baicalin reduces blood lipids and inflammation in patients with both CAD and RA, supporting its further clinical application.
类风湿关节炎（RA）患者的冠状动脉疾病（CAD）风险高于基线水平。黄芩苷对 RA 和 CAD 均有有益作用，但在同时患有 CAD 和 RA 的患者中，其临床疗效知之甚少。
374 例 CAD 和 RA 患者随机接受 500mg 黄芩苷或安慰剂口服，每天一次，共 12 周。在研究期末分析血脂谱、心肌营养素-1（CT-1）、高敏 C 反应蛋白（hs-CRP）、欧洲抗风湿病联盟（EULAR）反应。
经过 12 周治疗，与安慰剂组相比，黄芩苷组的甘油三酯、总胆固醇、LDL-胆固醇和载脂蛋白水平以及 CT-1 和 hs-CRP 均显著改善（1.12±0.36 与 1.87±0.46mmol/L、2.87±1.23 与 3.22±1.07mmol/L、1.38±0.41 与 1.16±0.32mmol/L、1.31±0.41 与 1.23±0.29g/L、42.9±13.7 与 128.4±24.3ng/mL、1.64±0.38 与 3.9±1.4mg/dL，分别）。黄芩苷组（71%）报告 EULAR 良好/中度反应的患者比例明显高于安慰剂组（53%）。
黄芩苷可降低 CAD 和 RA 患者的血脂和炎症，支持其进一步的临床应用。
